Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
BIOCRYST PHARMACEUTICALS INC (BCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "BioCryst Reports Second Quarter 2023 Financial Results and Provides Business Update"
07/11/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/30/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/03/2023 8-K Quarterly results
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/14/2023 SC 13G/A BAKER BROS. ADVISORS LP reports a 10% stake in BioCryst Pharmaceuticals, Inc.
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 8-K Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits  I...
Docs: "BioCryst Announces Preliminary Full Year 2022 ORLADEYO® Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue Guidance",
"BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated Diseases"
12/15/2022 8-K Quarterly results
11/04/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/01/2022 8-K Quarterly results
09/14/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer"
08/31/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/25/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment, to the Contract between BioCryst Pharmaceuticals, Inc. and the Department of Health and Human Services",
"U.S. Government Exercises Option to Purchase Additional RAPIVAB® from BioCryst for Pandemic Influenza Preparedness"
08/05/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
07/14/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/07/2022 8-K Quarterly results
05/26/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/05/2022 8-K Quarterly results
04/25/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/11/2022 8-K Regulation FD Disclosure  Interactive Data
04/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioCryst Pauses Enrollment in BCX9930 Clinical Trials"
02/28/2022 10-K Annual Report for the period ended December 31, 2021
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy